Ranbaxy shares fall on FDA concerns
Reuters Market Eye - Ranbaxy Laboratories(RANB.NS) shares fall 2 percent, adding to Monday's 5.4 percent slump after the U.S. Food and Drug Administration raised concerns about manufacturing practices at one of its factories.
Macquarie and Jefferies downgrade Ranbaxy, saying the FDA uncertainty could put pressure on valuations in the near-term till further clarity emerges.
Macquarie downgrades the stock to "neutral" from "outperform" and cuts the price target to 450 rupees from 500 rupees, while Jefferies cuts Ranbaxy to "underperform" from "hold" with a price target of 350 rupees.
Ranbaxy said on Monday the FDA has filed "certain observations" about its Toansa pharmaceutical ingredients plant in Punjab.
"The issue also increases the risk of delay in resolution of import alerts and launch of products," Jefferies said in a note to clients.
(Reporting by Indulal PM)
- Tweet this
- Share this
- Digg this
- Plague in Madagascar has killed 40 people out of 119 cases -WHO
- Widespread flooding ahead for snowy western New York: officials |
- U.S., Iran discussing new ideas to break nuclear impasse - sources
- Pakistani family sentenced to death over "honour killing" outside court
- Video streaming service Aereo files for bankruptcy
Prime Minister Narendra Modi has a long list of pro-growth measures to implement over the next four months, but time may have already run out to breathe enough life into the economy to meet the tough 2014/15 fiscal deficit target without cuts. Article